NCT06571734
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06571734
Title XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Northwestern University
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.